Fourth Quarter & Full Year 2022 Financial & Business Update

2023 Financial Outlook Reflects Portfolio Sales and Total Revenue Growth Net product sales¹ Revenues $1,925 to $2,000 million Royalty revenues Collaboration and license agreement revenues $170 to $185 million $45 to $55 million Total revenues Cost of sales $2,140 to $2,240 million Expenses $420 to $470 million R&D expenses $1,425 to $1,525 million SG&A expenses Non-cash expenses² $880 to $930 million $330 to $375 million • Revenues • Net product sales expected to be $1,925 million to $2,000 million, representing 13-17% growth over 2022 primarily driven by ADCETRIS and PADCEV Royalty revenues reflect increasing sales of ADCETRIS by Takeda in its territories and higher royalties on sales of POLIVY by Roche Collaboration and license agreement revenues include royalties from Astellas for PADCEV sales in its territories, as well as other collaboration activities Expenses • • Cost of sales driven by increased product sales, higher profit share payment to our collaborators, third-party royalties, and non-cash amortization expense R&D expense growth driven by investment to expand commercial products, advance our earlier-stage agents and drive ADC innovation SG&A expenses to support commercial execution to drive growth of our approved products and support our overall growth strategy 1 Net Products Sales include sales of ADCETRIS, PADCEV, TUKYSA and TIVDAK; 2 Primarily attributable to share-based compensation expense distributed Seagen approximately evenly between SG&A and R&D 20 20

View entire presentation